Musculoskeletal Diseases: Osteoporosis Musculoskeletal Diseases Osteoporosis
Conditions
Interventions
Intervention subjects will have a 10-year absolute risk of fracture calculated from a World Health Organization (WHO) risk algorithm based on data from a screening questionnaire and, for some subjects
Sponsors
University of East Anglia (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Female 2. Aged 70 to 85 years 3. Able to provide informed consent
Exclusion criteria
Exclusion criteria: 1. Currently known to be on treatment for osteoporosis (other than calcium and vitamin D) 2. Any known co-morbidity that would make entry to the trial inadvisable, in GP's opinion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All osteoporosis-related fractures (excluding those of hands, feet, nose and skull), assessed at the annual follow-up visits for 5 years post randomisation. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. All clinical fractures (including hip fractures) 2. Quality of life, assessed by the European Quality of life (EQ-5D) and Short Form 12 (SF-12) questionnaires at baseline (immediately prior to randomisation), 6 and 12 months and then annually for 5 years post randomisation 3. Psychological anxiety, assessed by the State-Trait Anxiety Index at baseline, 6 and 12 months and then annually for 5 years post randomisation 4. Mortality (assessed annually for 5 years post randomisation) A process measure will be treatment adherence as ascertained by an ad-hoc questionnaire at follow-up visits. | — |
Countries
United Kingdom
Outcome results
None listed